HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark C Genovese Selected Research

tofacitinib

5/2016Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
1/2016Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
3/2012Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark C Genovese Research Topics

Disease

126Rheumatoid Arthritis
12/2023 - 03/2002
38Infections
01/2023 - 05/2004
14Necrosis
01/2021 - 06/2007
12Psoriatic Arthritis
11/2021 - 05/2007
10Neoplasms (Cancer)
06/2022 - 01/2003
8Herpes Zoster
01/2023 - 01/2017
8Arthritis (Polyarthritis)
12/2021 - 09/2005
7Pain (Aches)
11/2020 - 04/2013
7Fatigue
01/2019 - 04/2006
6Rheumatic Diseases (Rheumatism)
12/2021 - 01/2003
6Psoriasis (Pustulosis Palmaris et Plantaris)
11/2021 - 05/2007
6Synovitis
11/2020 - 02/2011
6Inflammation (Inflammations)
01/2020 - 05/2011
5Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/2023 - 03/2002
5Osteitis
11/2020 - 04/2011
5Chronic Disease (Chronic Diseases)
01/2019 - 09/2006
4Injection Site Reaction
12/2020 - 05/2004
4Headache (Headaches)
04/2020 - 03/2012
4Neutropenia
01/2018 - 05/2004
3Sarcoidosis (Schaumann Disease)
07/2023 - 01/2020
3Respiratory Tract Infections (Respiratory Tract Infection)
04/2020 - 01/2018
3Autoimmune Diseases (Autoimmune Disease)
01/2009 - 03/2002
2Multiple Sclerosis
08/2023 - 01/2023
2Anemia
06/2022 - 04/2020
2Axial Spondyloarthritis
11/2021 - 12/2020
2Breakthrough Infections
10/2020 - 06/2020
2Opportunistic Infections (Opportunistic Infection)
10/2020 - 01/2019
2Granulomatous Mastitis
01/2020 - 07/2009
2Nasopharyngitis
01/2019 - 01/2018
2Hypersensitivity (Allergy)
11/2018 - 11/2018
2Urinary Tract Infections (Urinary Tract Infection)
01/2018 - 03/2012
2Hypertension (High Blood Pressure)
12/2015 - 06/2005
2Ankylosing Spondylitis
01/2014 - 06/2007
1Venous Thromboembolism
06/2022
1Cough
11/2020

Drug/Important Bio-Agent (IBA)

49Methotrexate (Mexate)FDA LinkGeneric
01/2021 - 06/2002
24Antirheumatic Agents (DMARD)IBA
06/2022 - 09/2005
19Adalimumab (Humira)FDA Link
01/2021 - 05/2007
16Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2021 - 09/2005
13baricitinibIBA
10/2020 - 02/2015
12Monoclonal AntibodiesIBA
07/2021 - 09/2008
11sarilumabIBA
07/2023 - 09/2014
11Etanercept (Enbrel)FDA Link
01/2020 - 06/2002
9Tumor Necrosis Factor InhibitorsIBA
11/2021 - 06/2010
9Abatacept (Orencia)FDA Link
01/2018 - 09/2005
8golimumabFDA Link
02/2016 - 06/2010
7GLPG0634IBA
01/2023 - 01/2019
7Janus Kinase InhibitorsIBA
01/2023 - 03/2012
6Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
07/2023 - 10/2008
6ixekizumabIBA
11/2021 - 07/2014
6Biomarkers (Surrogate Marker)IBA
11/2020 - 06/2005
6Biosimilar PharmaceuticalsIBA
11/2020 - 10/2017
6C-Reactive ProteinIBA
01/2019 - 10/2008
6tocilizumab (atlizumab)FDA Link
06/2017 - 10/2008
6ametantrone (HAQ)IBA
01/2017 - 09/2006
5Janus KinasesIBA
01/2023 - 01/2019
5Interleukin-17 (Interleukin 17)IBA
11/2018 - 01/2012
5LipidsIBA
01/2017 - 01/2014
5fostamatinibIBA
12/2015 - 02/2011
4CytokinesIBA
01/2021 - 06/2007
4Infliximab (Remicade)FDA Link
01/2020 - 06/2004
4upadacitinibIBA
11/2019 - 12/2016
4AntigensIBA
01/2016 - 09/2005
4Syk KinaseIBA
12/2014 - 09/2010
4AutoantibodiesIBA
01/2009 - 03/2002
3Interleukin-6 (Interleukin 6)IBA
07/2023 - 06/2007
3omega-Chloroacetophenone (Mace)IBA
01/2023 - 01/2019
3Agammaglobulinaemia Tyrosine KinaseIBA
01/2023 - 04/2020
3InterleukinsIBA
07/2021 - 06/2007
3FKB327IBA
11/2020 - 12/2019
3Transaminases (Aminotransferases)IBA
01/2017 - 09/2014
3tofacitinibIBA
05/2016 - 03/2012
3secukinumabIBA
01/2016 - 06/2013
3CreatinineIBA
01/2016 - 04/2002
3B-Cell Activating FactorIBA
08/2015 - 09/2013
3tabalumabIBA
08/2015 - 09/2013
3Rituximab (Mabthera)FDA Link
06/2010 - 09/2006
2evobrutinibIBA
08/2023 - 01/2023
2SteroidsIBA
07/2023 - 02/2011
2olokizumabIBA
07/2021 - 09/2014
2Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
11/2020 - 06/2007
2peficitinibIBA
12/2019 - 01/2017
2Creatine Kinase (Creatine Phosphokinase)IBA
11/2019 - 06/2007
2ABT-122IBA
11/2018 - 11/2018
2Janus Kinase 1IBA
01/2018 - 03/2016
2ChemokinesIBA
01/2018 - 06/2007
2Lipoproteins (Lipoprotein)IBA
01/2017 - 01/2016
22- ((2- (1H- pyrrolo(2,3- b)pyridin- 3- yl)pyrimidin- 4- yl)amino)- 2- methyl- N- (2,2,2- trifluoroethyl)butanamideIBA
11/2016 - 01/2016
2brodalumabIBA
02/2016 - 06/2014
2Phosphotransferases (Kinase)IBA
10/2015 - 10/2006
2Immunoglobulins (Immunoglobulin)IBA
08/2015 - 04/2002
2Interleukin-17 ReceptorsIBA
06/2014 - 01/2012
1salicylhydroxamic acid (SHAM)IBA
12/2023
1GlucocorticoidsIBA
07/2023
1poseltinibIBA
01/2021
1CC ChemokinesIBA
11/2020
1OtilimabIBA
11/2020

Therapy/Procedure

37Therapeutics
07/2023 - 06/2002
4Vagus Nerve Stimulation
12/2023 - 09/2020
2Biological Therapy
02/2011 - 06/2005